Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.

Subgroup analyses showed a trend toward a greater PFS and OS benefit for patients randomized early after completion of radiotherapy (<14 days). 48 – 50 The safety profiles were similar between arms, with 30.5% vs 26.1% grade ≥3 AEs, including pneumonitis (3.6% vs 2.4%); 15.4% durvalumab and 9.8% placebo treated patients discontinued the regimen due to AEs. 48 , 49 Treatment exposure was similar in patients with or without pneumonitis across both arms as was median time to onset of pneumonitis from treatment start (55.0 days).

also in 53,322 other papers